COMPOSITION FOR DIAGNOSING METASTATIC OVARIAN CANCER USING CpG METHYLATION CHANGE OF AN IFITM1 GENE PROMOTER, AND A USE THEREOF

摘要

PURPOSE: A composition for diagnosing metastatic ovarian cancer is provided to measure methylation levels of a certain gene promoter site of genome DNA isolated from a patient's sample by MSP(Methylation-Specific PCR), to quickly diagnose the risk of metastasis, and to develop a convenient diagnostic kit with high accuracy.;CONSTITUTION: A composition for diagnosing ovarian cancer metastasis or the risk of metastasis contains an agent which measures methylation levels of CpG site of an IFITM1(interferon-induced transmembrane 1) gene promoter. The agent contains: a compound which modifies non-methylated cytosine or a methylation-sensitive restriction enzyme; a primer which is specific to a methylated sequence of a GABRP gene promoter; and a primer which is specific to a non-methylated sequence of the GABRP gene promoter. A method for measuring methylation levels of CpG site comprises: a step of treating genome DNA with the compound which modifies non-methylated cytosine or the methylation-sensitive restriction enzyme; and a step of amplifying the treated DNA by PCR using a primer which amplifies CpG site.;COPYRIGHT KIPO 2013